PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34270985-0	2021	Inhibition of autophagy by YC-1 promotes gefitinib induced apoptosis by targeting FOXO1 in gefitinib-resistant NSCLC cells.	Gefitinib	41-50	RNA binding motif single stranded interacting protein 1	Homo sapiens	27-31	
34270985-0	2021	Inhibition of autophagy by YC-1 promotes gefitinib induced apoptosis by targeting FOXO1 in gefitinib-resistant NSCLC cells.	Gefitinib	91-100	RNA binding motif single stranded interacting protein 1	Homo sapiens	27-31	
34270985-6	2021	In the present study, YC-1, an inhibitor of HIF-1alpha, was first found to significantly inhibit the autophagy induced by gefitinib by disrupting the fusion of autophagosomes and lysosomes and thereby enhancing the proapoptotic effect of gefitinib in gefitinib-resistant NSCLC cells.	Gefitinib	122-131	RNA binding motif single stranded interacting protein 1	Homo sapiens	22-26	
34270985-6	2021	In the present study, YC-1, an inhibitor of HIF-1alpha, was first found to significantly inhibit the autophagy induced by gefitinib by disrupting the fusion of autophagosomes and lysosomes and thereby enhancing the proapoptotic effect of gefitinib in gefitinib-resistant NSCLC cells.	Gefitinib	238-247	RNA binding motif single stranded interacting protein 1	Homo sapiens	22-26	
34270985-6	2021	In the present study, YC-1, an inhibitor of HIF-1alpha, was first found to significantly inhibit the autophagy induced by gefitinib by disrupting the fusion of autophagosomes and lysosomes and thereby enhancing the proapoptotic effect of gefitinib in gefitinib-resistant NSCLC cells.	Gefitinib	251-260	RNA binding motif single stranded interacting protein 1	Homo sapiens	22-26	
34270985-7	2021	Furthermore, the combinational anti-autophagic and pro-apoptotic effect of gefitinib and YC-1 was demonstrated to be associated with an enhanced of forkhead box protein O1 (FOXO1) transcriptional activity which resulted from an increase in the p-FOXO1 protein level in gefitinib-resistant NSCLC cells.	Gefitinib	269-278	RNA binding motif single stranded interacting protein 1	Homo sapiens	89-93	
32044322-0	2020	YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1alpha and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.	Gefitinib	43-52	RNA binding motif single stranded interacting protein 1	Homo sapiens	0-4	
32044322-0	2020	YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1alpha and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.	Gefitinib	145-154	RNA binding motif single stranded interacting protein 1	Homo sapiens	0-4	
32044322-3	2020	Here, we showed that a HIF-1alpha inhibitor, YC-1, potentiated the antitumor efficacy of gefitinib by promoting EGFR degradation in a panel of human NSCLC cells with wild-type or mutant EGFRs.	Gefitinib	89-98	RNA binding motif single stranded interacting protein 1	Homo sapiens	45-49	
32044322-4	2020	YC-1 alone had little effect on NSCLC cell survival but significantly enhanced the antigrowth and proapoptotic effects of gefitinib.	Gefitinib	122-131	RNA binding motif single stranded interacting protein 1	Homo sapiens	0-4	
32044322-5	2020	In insensitive NSCLC cell lines, gefitinib efficiently inhibited the phosphorylation of EGFR but not the downstream signaling of ERK, AKT and STAT3; however, when combined with YC-1 treatment, these signaling pathways were strongly impaired.	Gefitinib	33-42	RNA binding motif single stranded interacting protein 1	Homo sapiens	177-181	
32044322-9	2020	Our findings provide a novel combination treatment strategy with gefitinib and YC-1 to extend the usage of gefitinib and overcome gefitinib resistance in NSCLC patients.	Gefitinib	107-116	RNA binding motif single stranded interacting protein 1	Homo sapiens	79-83	
32044322-9	2020	Our findings provide a novel combination treatment strategy with gefitinib and YC-1 to extend the usage of gefitinib and overcome gefitinib resistance in NSCLC patients.	Gefitinib	107-116	RNA binding motif single stranded interacting protein 1	Homo sapiens	79-83